Phantom Neuro announced today that it formally opened its patient registry to connect individuals to upcoming clinical studies and research opportunities.
The Austin, Texas–based company said its new initiative aims to open up opportunities for individuals with upper limb amputations. It invites amputees, clinicians and rehabilitation specialists to sign up for updates on future trials and early access programs.
Information from interested participants can help the company better understand needs. It can also accelerate study readiness and ensure diverse representation in its ongoing research.
This marks the latest milestone as Phantom Neuro is looking to bring its Phantom X robotic control platform to patients. The neurotech company designed Phantom X as a minimally invasive neural interface. Implanted just beneath the skin in an outpatient procedure, it provides intuitive control of prosthetics and robotic devices.
The platform uses algorithms to decode natural human movement and provide a near-human experience when controlling prosthetic limbs and assistive technologies. The company previously touted a study demonstrating 94% accuracy in decoding real-time gestures across 11 essential hand and rist movements with Phantom X.
Phantom Neuro won FDA breakthrough device designation for the technology in March. It then raised $19 million in a Series A financing round in April, bringing its total funding to $28 million.
“Innovation in neurotechnology must start and end with the patient,” said Dr. Connor Glass, CEO and founder of Phantom Neuro. “This registry allows us to engage directly with the amputee community, building relationships, understanding real-world challenges, and preparing for future studies that reflect the diversity and priorities of those we serve.”
